AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11719144 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR with audio feedback from the manikin
Number of subjects: 24
Study 11719144 — intervention group
Group type: COMPARATOR
Intervention: CPR without feedback
Number of subjects: 24
Study 9225069 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony‐stimulating factor (G‐CSF) and erythropoietin (EPO)
Number of subjects: 51
Study 9225069 — intervention group
Group type: COMPARATOR
Intervention: Patients with MDS
Number of subjects: 51
Study 9225069 — intervention group
Group type: COMPARATOR
Intervention: Patients with RAS
Number of subjects: 51
Study 9225069 — intervention group
Group type: COMPARATOR
Intervention: Patients with RAEB
Number of subjects: 51
Study 7954488 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 200 mg b.i.d.
Number of subjects: 34
Study 7954488 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine 75 mg b.i.d.
Number of subjects: 34
Study 7954488 — intervention group
Group type: COMPARATOR
Intervention: Mianserin 10 mg t.i.d.
Number of subjects: 34
Study 7954488 — intervention group
Group type: COMPARATOR
Intervention: Doxepin 25 mg t.i.d.
Number of subjects: 34
Study 7954488 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine (both doses)
Number of subjects: 34
Study 7954488 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 34
Study 7954488 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (Moclobemide and Brofaromine)
Number of subjects: 34
Study 3302005 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg twice daily
Number of subjects: 84
Study 3302005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 2359974 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscous bolus (syrup; viscosity, 102 centipoise) at varying volumes (5, 10, 15, 20 ml)
Number of subjects: 0
Study 2359974 — intervention group
Group type: COMPARATOR
Intervention: Non-viscous bolus (water; viscosity, 0.89 centipoise) at varying volumes (5, 10, 15, 20 ml)
Number of subjects: 0
Study 1228216 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (5-10 and 15 mulli-units per minute)
Number of subjects: 50
Study 1228216 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha (12.5-25 and 37.5 microgrammes per minute)
Number of subjects: 50
Study 1228216 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin or Prostaglandin F2 alpha
Number of subjects: 50
Study 31848703 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + BFR
Number of subjects: 30
Study 31848703 — intervention group
Group type: EXPERIMENTAL
Intervention: RT
Number of subjects: 30
Study 31848703 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 31473510 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal supplemented with blueberry powder
Number of subjects: 5
Study 31473510 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal supplemented with docosahexaenoic acid (DHA)
Number of subjects: 5
Study 31473510 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal supplemented with placebo
Number of subjects: 5
Study 31473510 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal postprandial response
Number of subjects: 5
Study 31473510 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject-specific postprandial responses
Number of subjects: 5
Study 31473510 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring gene expression at multiple time points
Number of subjects: 5
Study 27856150 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-fluorescence guided bone surgery
Number of subjects: 40
Study 27856150 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline fluorescence guided bone surgery
Number of subjects: 40
Study 25887849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package including use of a new continuum of care card, orientation for health workers, 24-hour health facility retention, and postnatal care by home visits.
Number of subjects: 0
Study 25887849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package
Number of subjects: 0
Study 23584162 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 100
Study 23584162 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral instrumented fusion (PLF)
Number of subjects: 100
Study 22044568 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship-based intervention
Number of subjects: 15
Study 22044568 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 15
Study 19683927 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiofrequency (CRF)
Number of subjects: 50
Study 19683927 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigeminal peripheral division radiofrequency thermocoagulation (PRT)
Number of subjects: 50
Study 17851860 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte-depleted red blood cells (LDB)
Number of subjects: 642
Study 17851860 — intervention group
Group type: COMPARATOR
Intervention: Packed red blood cells (RBC)
Number of subjects: 642
Study 17851860 — intervention group
Group type: COMPARATOR
Intervention: Non-transfused patients
Number of subjects: 642
Study 12556685 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% PRO 2000 Gel, once or twice daily for 14 days
Number of subjects: 63
Study 12556685 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% PRO 2000 Gel, twice daily for 14 days
Number of subjects: 63
Study 12556685 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 63
Study 10642968 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic Stimulation Test (AST)
Number of subjects: 400
Study 10642968 — intervention group
Group type: COMPARATOR
Intervention: Nonstress Test (NST)
Number of subjects: 400
Study 8546555 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine alone
Number of subjects: 9336
Study 8546555 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza and pneumococcal vaccines
Number of subjects: 9336
Study 2064515 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-K antagonists and dipyridamole
Number of subjects: 469
Study 2064515 — intervention group
Group type: COMPARATOR
Intervention: Vitamin-K antagonists and placebo
Number of subjects: 469
Study 6342785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclacillin, administered three times a day for ten days
Number of subjects: 134
Study 6342785 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin, administered similarly
Number of subjects: 134
Study 30916714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 52
Study 30916714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 28497480 — intervention group
Group type: EXPERIMENTAL
Intervention: p‐EVES (portable electronic vision enhancement systems)
Number of subjects: 100
Study 28497480 — intervention group
Group type: COMPARATOR
Intervention: Optical aids only
Number of subjects: 100
Study 28497480 — intervention group
Group type: EXPERIMENTAL
Intervention: p‐EVES
Number of subjects: 100
Study 27245042 — intervention group
Group type: EXPERIMENTAL
Intervention: Jingui Shenqi pill combined with nifedipine sustained-release tablets
Number of subjects: 96
Study 27245042 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine sustained-release tablets
Number of subjects: 96
Study 24179979 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma cleaning/sterilisation
Number of subjects: 20
Study 24179979 — intervention group
Group type: COMPARATOR
Intervention: 5-second steam cleaning
Number of subjects: 20
Study 21253001 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person condition
Number of subjects: 323
Study 21253001 — intervention group
Group type: COMPARATOR
Intervention: Internet condition
Number of subjects: 323
Study 19388835 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed primary closure (DPC)
Number of subjects: 77
Study 19388835 — intervention group
Group type: COMPARATOR
Intervention: Primary closure (PC)
Number of subjects: 77
Study 16715189 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg methylprednisolone (Group I)
Number of subjects: 40
Study 16715189 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group II)
Number of subjects: 40
Study 15278206 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix‐guided autologous chondrocyte implantation (MACI)
Number of subjects: 27
Study 15278206 — intervention group
Group type: COMPARATOR
Intervention: Microfracture (MFX)
Number of subjects: 27
Study 10865157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 235
Study 10865157 — intervention group
Group type: COMPARATOR
Intervention: Structured exercise intervention
Number of subjects: 235
Study 10865157 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 235
Study 9105094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg)
Number of subjects: 10
Study 9105094 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (10 mg)
Number of subjects: 10
Study 9105094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1435827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-phosphate cow's milk
Number of subjects: 31
Study 1435827 — intervention group
Group type: COMPARATOR
Intervention: Conventional cow's milk
Number of subjects: 31
Study 3894216 — intervention group
Group type: EXPERIMENTAL
Intervention: Butoconazole nitrate cream (3-day course)
Number of subjects: 100
Study 3894216 — intervention group
Group type: COMPARATOR
Intervention: Miconazole nitrate cream (7-day course)
Number of subjects: 100
Study 30725428 — intervention group
Group type: EXPERIMENTAL
Intervention: WLS Forte®
Number of subjects: 148
Study 30725428 — intervention group
Group type: COMPARATOR
Intervention: sMVS
Number of subjects: 148
Study 29643323 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin (5 mg once daily)
Number of subjects: 355
Study 29643323 — intervention group
Group type: COMPARATOR
Intervention: voglibose (0.2 mg/meal thrice daily)
Number of subjects: 355
Study 28699565 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilisation for dengue prevention (intervention clusters)
Number of subjects: 12312
Study 28699565 — intervention group
Group type: COMPARATOR
Intervention: Control (control clusters)
Number of subjects: 12312
Study 25316485 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node based management (SNBM)
Number of subjects: 1088
Study 25316485 — intervention group
Group type: COMPARATOR
Intervention: Routine axillary clearance (RAC)
Number of subjects: 1088
Study 22891893 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV‐C (immune globulin intravenously)
Number of subjects: 117
Study 22891893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 22891893 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV‐C
Number of subjects: 117
Study 21397284 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrogenated soybean oil (15 g/d TFA)
Number of subjects: 52
Study 21397284 — intervention group
Group type: COMPARATOR
Intervention: Control oil (mainly oleic and palmitic acid)
Number of subjects: 52
Study 18270137 — intervention group
Group type: EXPERIMENTAL
Intervention: Active filling of the left atrium by a line from the aortic cannula and venting from the antegrade cardioplegia line (Group 1)
Number of subjects: 40
Study 18270137 — intervention group
Group type: COMPARATOR
Intervention: Ventilating the lungs and venting from the antegrade cardioplegia line without active filling of the left atrium (Group 2)
Number of subjects: 40
Study 16194527 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cue presented in corresponding anatomical location on a model's body
Number of subjects: 0
Study 16194527 — intervention group
Group type: COMPARATOR
Intervention: Visual cue presented on a non-body control stimulus
Number of subjects: 0
Study 12974687 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups A-D (brushed after different times post-erosion: A - immediately, B - 20 min, C - 40 min, D - 60 min)
Number of subjects: 120
Study 12974687 — intervention group
Group type: COMPARATOR
Intervention: Control group E (only acid-eroded)
Number of subjects: 120
Study 12974687 — intervention group
Group type: COMPARATOR
Intervention: Control group F (only brushed)
Number of subjects: 120
Study 10719945 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (n = 40)
Number of subjects: 160
Study 10719945 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (tranexamic acid with autologous blood collection, n = 32)
Number of subjects: 160
Study 10719945 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (saline infusion, n = 43)
Number of subjects: 160
Study 9267667 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell depleted marrow grafts
Number of subjects: 92
Study 9267667 — intervention group
Group type: COMPARATOR
Intervention: Unmodified marrow grafts
Number of subjects: 92
Study 9267667 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DR beta 1 and DQ beta matching
Number of subjects: 92
Study 9267667 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving a T-cell depleted graft
Number of subjects: 92
Study 7504977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of aprotinin
Number of subjects: 60
Study 7504977 — intervention group
Group type: COMPARATOR
Intervention: Classical doses of aprotinin
Number of subjects: 60
Study 7504977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 60
Study 7504977 — intervention group
Group type: COMPARATOR
Intervention: Low-dosed aprotinin
Number of subjects: 60
Study 7504977 — intervention group
Group type: COMPARATOR
Intervention: Classical and reduced aprotinin dosages
Number of subjects: 60
Study 3797115 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural human surfactant (60 mg surfactant/kg body weight)
Number of subjects: 29
Study 3797115 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 29
Study 3797115 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural human surfactant
Number of subjects: 29
Study 28870494 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth care coordination intervention delivered by advanced practice registered nurses
Number of subjects: 163
Study 28870494 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HRQL and presence of neurologic impairment and technology dependence
Number of subjects: 163
Study 27737646 — intervention group
Group type: EXPERIMENTAL
Intervention: 4200 IU/week vitamin D supplementation from 2nd trimester to delivery plus placebo from 0-6 months postpartum
Number of subjects: 1300
Study 27737646 — intervention group
Group type: EXPERIMENTAL
Intervention: 16800 IU/week vitamin D supplementation from 2nd trimester to delivery plus placebo from 0-6 months postpartum
Number of subjects: 1300
Study 27737646 — intervention group
Group type: EXPERIMENTAL
Intervention: 28000 IU/week vitamin D supplementation from 2nd trimester to delivery plus placebo from 0-6 months postpartum
Number of subjects: 1300
Study 27737646 — intervention group
Group type: EXPERIMENTAL
Intervention: 28000 IU/week prenatal and until 6 months postpartum
Number of subjects: 1300
Study 27737646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1300
Study 24219822 — intervention group
Group type: EXPERIMENTAL
Intervention: HDWLE + eCLE + TB
Number of subjects: 192
Study 24219822 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo CLE
Number of subjects: 192
Study 24219822 — intervention group
Group type: COMPARATOR
Intervention: HDWLE + RB
Number of subjects: 192
Study 23551243 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral vitamin D3 supplementation (2000 IU per day for 30 days)
Number of subjects: 0
Study 23551243 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated summer UV exposure (10 sunbed sessions to a total dose of 23.8 SED)
Number of subjects: 0
Study 23551243 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (oral vitamin D3 and UV exposure)
Number of subjects: 0
Study 23551243 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body sunbed exposure (4.8 SED twice weekly)
Number of subjects: 0
Study 19501354 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg triptorelin (group A; n=172)
Number of subjects: 344
Study 19501354 — intervention group
Group type: COMPARATOR
Intervention: Solvent only (group B; n=172)
Number of subjects: 344
Study 18978272 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional (3D) reconstruction plate
Number of subjects: 133
Study 18978272 — intervention group
Group type: COMPARATOR
Intervention: Superior plate
Number of subjects: 133
Study 16681719 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m(2) on day 1 and gemcitabine 1250 mg/m(2) on days 1 and 8, sequence T‐‐>G
Number of subjects: 39
Study 16681719 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m(2) and paclitaxel 175 mg/m(2)
Number of subjects: 39
Study 16681719 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m(2) and paclitaxel 150 mg/m(2)
Number of subjects: 39
Study 16681719 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m(2) and paclitaxel 175 mg/m(2) with sequence G‐‐>T
Number of subjects: 39
Study 12809965 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use (1892 patients, 21.9% of total); mean TC level of 5.99 mmol/L (231.6 mg/dL) at end of study; 1096 patients (57.9%) had TC levels above cutoff.
Number of subjects: 8653
Study 12809965 — intervention group
Group type: COMPARATOR
Intervention: No statin use (6761 patients, 78.1% of total); mean TC level of 6.24 mmol/L (241.4 mg/dL) at end of study; 5316 patients (78.6%) had TC levels above cutoff.
Number of subjects: 8653
Study 11182393 — intervention group
Group type: EXPERIMENTAL
Intervention: Subareolar injection of technetium‐99 sulfur colloid and blue dye
Number of subjects: 38
Study 11182393 — intervention group
Group type: COMPARATOR
Intervention: Peritumoral injection of technetium‐99 sulfur colloid and blue dye
Number of subjects: 38
Study 7641751 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-99m HMPAO SPET
Number of subjects: 27
Study 7641751 — intervention group
Group type: COMPARATOR
Intervention: CT scan
Number of subjects: 27
Study 2496149 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine, 100 mg daily for 17 days
Number of subjects: 0
Study 2496149 — intervention group
Group type: COMPARATOR
Intervention: Clovoxamine, 150 mg daily for 17 days
Number of subjects: 0
Study 323023 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolamolol (300 mg/day - 900 mg/day)
Number of subjects: 13
Study 323023 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (750 mg/day - 2250 mg/day)
Number of subjects: 13
Study 323023 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa (Control)
Number of subjects: 13
Study 31880827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat adaptation condition
Number of subjects: 0
Study 31880827 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat adaptation condition
Number of subjects: 0
Study 31880827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-muscle adaptation condition
Number of subjects: 0
Study 31880827 — intervention group
Group type: EXPERIMENTAL
Intervention: High-muscle adaptation condition
Number of subjects: 0
Study 31711300 — intervention group
Group type: EXPERIMENTAL
Intervention: Household water quality self-testing and receipt of information (handouts) on improving water quality
Number of subjects: 512
Study 31711300 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 512
Study 28290704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-joint mobilization (AJM)
Number of subjects: 59
Study 28290704 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar massage (PM)
Number of subjects: 59
Study 28290704 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf stretching (CS)
Number of subjects: 59
Study 26682608 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week gross motor skills program (10 min. daily)
Number of subjects: 60
Study 24135213 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐couch program (unguided Web‐based program based on cognitive behavioral therapy and interpersonal therapy)
Number of subjects: 280
Study 24135213 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐couch program
Number of subjects: 280
Study 20605477 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular nerve block (MNB) with 5 mL ropivacaine 0.5% for each block
Number of subjects: 38
Study 20605477 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular nerve block (MNB)
Number of subjects: 38
Study 20605477 — intervention group
Group type: COMPARATOR
Intervention: Sham MNB (Control)
Number of subjects: 38
Study 18348597 — intervention group
Group type: EXPERIMENTAL
Intervention: memantine 20 mg/day
Number of subjects: 80
Study 18348597 — intervention group
Group type: COMPARATOR
Intervention: escitalopram 20 mg/day
Number of subjects: 80
Study 17146409 — intervention group
Group type: EXPERIMENTAL
Intervention: m-CPP 0.5 mg/kg
Number of subjects: 52
Study 17146409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 14586322 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal age >= 40 years
Number of subjects: 6188
Study 14586322 — intervention group
Group type: COMPARATOR
Intervention: Paternal age < 40 years
Number of subjects: 6188
Study 11063437 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA diet (20.3 +/- 3.5% of total energy)
Number of subjects: 9
Study 11063437 — intervention group
Group type: EXPERIMENTAL
Intervention: High-PUFA diet (13.4 +/- 1.3% of total energy)
Number of subjects: 9
Study 11063437 — intervention group
Group type: COMPARATOR
Intervention: Standard test meal (identical for both diets)
Number of subjects: 9
Study 9057142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary fixation for femoral shaft fractures
Number of subjects: 46
Study 9057142 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed femoral shortening
Number of subjects: 46
Study 9057142 — intervention group
Group type: COMPARATOR
Intervention: Control group (asymptomatic)
Number of subjects: 46
Study 7943920 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg of triazolam p.o.
Number of subjects: 22
Study 7943920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22